Author:
Chao Chon Kit,Hu Hao,Zhang Liming,Wu Jihong
Abstract
Purpose
The paper aims to study how global pharmaceutical companies such as Pfizer have managed the challenges of pharmaceutical patent expiry.
Design/methodology/approach
A case study method was applied. The best-selling brand drug over the past 10 years – Lipitor – was chosen as the case target.
Findings
For dealing with this, this paper describes all the details of the corresponding strategies of Pfizer before and after patent expiration of Lipitor. Before patent expiry, Pfizer undertook the activities of direct-to-consumer marketing, pricing strategy for competition, legal delay and me-too drug R&D. After patent expiry, Pfizer chose to carry out continuous marketing for brand, rebate strategy, authorized generics and change to over-the-counter. In addition, diversity and globalization strategy was applied before and after patent expiry.
Research limitations/implications
This research provides strong implication for managing pharmaceutical products before and after patent expiry.
Practical implications
It is strongly recommended for both brand and generic drug companies to design strategies to meet the challenges of pharmaceutical patent expiry.
Social implications
For the global pharmaceutical market, a conclusion can be drawn that, nowadays, the “patent cliff” is the most significant factor influencing decision-makers to consider futuristic policies. Further, it is also a considerably effective solution for reducing health-care costs for policymakers.
Originality/value
This paper contributes to the field of patent expiry management in high-tech industries such as pharmaceuticals.
Reference53 articles.
1. Prescription drug spending trends in the US: looking beyond the turning point;Health Affairs,2009
2. Authorized generic entry prior to patent expiry: reassessing incentives for independent generic entry;Review of Economics and Statistics,2015
3. Pricing policies to handle patent loss or expiry;Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing,2003
4. Beasley, D. (2011), “Branded drug prices soar as generic pressure rises”, available at: www.reuters.com/article/2011/03/23/us-branded-drug-prices-idUSTRE72M57X20110323 (accessed 23 March 2011).
5. Pharmaceuticals in US health care: determinants of quantity and price;Journal of Economic Perspectives,2002
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献